Tina Joseph, PharmD, BCACP, assistant professor, college of pharmacy, Nova Southeastern University, discusses the role of pharmacists in helping manage chronic diseases and the transition for integrating pharmacists into value-based care models.
Tina Joseph, PharmD, BCACP, assistant professor, college of pharmacy, Nova Southeastern University, discusses the role of pharmacists in helping manage chronic diseases and the transition for integrating pharmacists into value-based care models.
Transcipt
What role do pharmacists have in helping the healthcare team manage chronic diseases?
There’s a huge roll for pharmacists to manage chronic diseases. The challenge with chronic diseases is that patients have to do a lot of work every single day to manage them. So, it can’t be like you give an antibiotic for a pneumonia for five days and then that’s it. With something like diabetes there’s a lot of emotional factors that go into it, there’s a lot of medications, diet, exercise, and monitoring the blood sugar. Pharmacists play a huge role and I think a lot of people are not aware that we can help educate them on diet, on exercise, and the medications. So, we play a huge role in not only that but also in motivating the patient. I think pharmacists are very natural communicators, because we’re always having to speak to patients and I think helping to be their cheerleader helping them understand what’s going on with their disease state is an important role for pharmacists.
How has the transition been for integrating pharmacists into value-based care models?
I would say in the beginning, this is my third year trying to attempt to integrate pharmacists into an accountable care organization and it has been challenging, but with that it’s very rewarding. Having the opportunity to speak to the corporate office, clinical, and staff, about the value of a pharmacist has been so rewarding. This is because now they are so interested, whereas in the past they really haven’t been because there has been no reimbursement tied to it. So, now that we have quality metrics that pharmacists can help with it’s a much easier conversation to have with these organizations.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More